Chemical Structure : TSL2109
Catalog No.: PC-26150Not For Human Use, Lab Use Only.
TSL2109 is a potent, selective, orally active Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) inhibitor with IC50 of 22 nM.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
TSL2109 is a potent, selective, orally active Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) inhibitor with IC50 of 22 nM.
TSL2109 displays potent inhibitory activity against DYRK2 at 1 uM, while exhibiting <50% inhibition against over 93% of a panel of 416 kinases.
TSL2109 effectively occupies the ATP-binding pocket of DYRK2.
TSL2109 exhibits potent antiproliferative activity (IC50=0.933 μM) and dose-dependent cell growth inhibitory activity against PCa DU145 cells.
TSL2109 significantly inhibits the E2F TARGETS and G2M CHECKPOINT pathways, both closely associated with cell cycle progression, significantly upregulates APOPTOSIS and P53 pathways.
TSL2109 (100-200 mg/kg) produced marked antitumor effects in the DU145 xenograft models.
TSL2109 exerted significant inhibitory effects against enzalutamide-resistant 22Rv1 cells and xenografts.
| M.Wt | 548.69 | |
| Formula | C28H33FN8OS | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Kai Yuan, et al. J Med Chem. 2025 Dec 25;68(24):25783-25793.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright